Eric Venker

President & Immunovant CEO

Eric Venker (President & Immunovant CEO) filed 17 Form 4 reports in the trailing twelve months (0 purchases, 17 sales, 1 filed past the two-business-day deadline), most often in Roivant Sciences Ltd. (ROIV). The largest single filing was $14.5M of ROIV (851,383 sh across 3 lots, as filed), executed Oct 15 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 17 sells · 1 late

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$90.2M

shares × price, as filed

Last traded

Aug 28

Filed Sep 1

Median ADV $222.0M across their filed names

Open performance→

Volume by month

Buys $0 Sells $155.0M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 16 filings

Sector per market data · by filing · past 12 months

Most traded names

ROIV

Roivant Sciences Ltd. ROIV · 0 buys · 29 sells 29 filings IMVT

Immunovant, Inc. IMVT · 0 buys · 2 sells 2 filings

Recent filings

ROIVSALE Roivant Sciences Ltd. View filing → $1.1M
100,000 sh × $10.65
Exec Feb 20 2025
Filed Feb 24 2025 · 5:30 PM ET ROIVSALE Roivant Sciences Ltd. View filing → $4.6M
435,425 sh across 2 lots
Exec Feb 12 2025
Filed Feb 14 2025 · 5:30 PM ET ROIVSALE Roivant Sciences Ltd. View filing → $1.1M
100,000 sh × $11.28
Exec Jan 21 2025
Filed Jan 22 2025 · 5:30 PM ET ROIVSALE Roivant Sciences Ltd. View filing → $4.1M
354,604 sh across 2 lots
Exec Dec 27 2024
Filed Dec 31 2024 · 5:30 PM ET